Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...